Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Palliative Care × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 24 Other hematologic neoplasm 18 Gastrointestinal 18 Thoracic 11 Gynecologic 11 Tumor-Agnostic 10 Lymphoid 8 Genitourinary 8 Other solid neoplasm 6 Plasma cell 5 CNS 5 Sarcoma 4 Head & Neck 4 Myeloid 3 Dermatologic 3 Endocrine 2 Other 1 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41 Everolimus 38 Magnetic Resonance Spectroscopy 18 Temozolomide 17 lanreotide 16 gallium Ga 68 dotatate 15 Octreotide 14 pembrolizumab 13 Nivolumab 13 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 9 pasireotide 9 Sunitinib 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Lutetium-177 8 Carboplatin 8 amino-acid, glucose, and electrolyte solution 6 Ipilimumab 6 Ga(III)-DOTATOC 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 copper dotatate CU-64 5 Injections 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01849523 2024-05-06

WIN

University Medical Center Groningen

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡